Pfizer Inc. $PFE Shares Acquired by Simplicity Wealth LLC

Simplicity Wealth LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 144.2% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 109,120 shares of the biopharmaceutical company’s stock after buying an additional 64,440 shares during the period. Simplicity Wealth LLC’s holdings in Pfizer were worth $2,628,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Evolution Wealth Management Inc. raised its stake in Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 566 shares during the last quarter. Godfrey Financial Associates Inc. purchased a new stake in Pfizer during the 4th quarter valued at about $26,000. Keb Asset Management LLC acquired a new stake in Pfizer in the 2nd quarter valued at about $26,000. HFM Investment Advisors LLC lifted its stake in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares in the last quarter. Finally, Global Trust Asset Management LLC lifted its stake in Pfizer by 126.7% in the 1st quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 650 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer completed a Phase 1/2 study of PF-07868489, an experimental treatment for pulmonary arterial hypertension. The milestone supports early-stage pipeline progress, though additional clinical testing will be needed before any potential commercialization. Pfizer’s PF-07868489 PAH Study Reaches Completion
• Positive Sentiment: Several additional clinical updates highlighted progress across Pfizer’s development portfolio: completion of a Phase 1 atirmociclib study, completion of a drug-interaction study for PF-07248144, and a new Phase 1 liver study for atirmociclib. These milestones may reinforce confidence in Pfizer’s ability to replenish revenue as older products face competition. Atirmociclib Study Update PF-07248144 Study Update
• Positive Sentiment: Pfizer is also expanding real-world evidence efforts for prostate cancer therapies, Ibrance in advanced breast cancer, and a migraine treatment study in India. These studies could support broader use and strengthen commercial evidence for existing medicines. Pfizer Real-World Prostate Cancer Study
• Positive Sentiment: Investor-oriented coverage remains constructive, citing Pfizer’s roughly 19% year-to-date gain, attractive dividend yield, and reported hedge-fund buying. The stock’s move toward its 52-week high suggests improving sentiment. Hedge Funds Buying Pfizer
• Neutral Sentiment: Unusually large options activity may increase short-term trading interest, but it does not establish a clear fundamental direction for PFE. Pfizer Options Trading
• Negative Sentiment: Coverage of settlements involving thousands of Depo-Provera lawsuits raises concerns about potential legal costs and ongoing liability. Analysts also continue to weigh whether new drugs and acquisitions can offset revenue losses from expiring patents. Pfizer Legal Claims

Pfizer Stock Performance

Pfizer stock opened at $28.00 on Friday. The firm has a 50 day simple moving average of $25.30 and a 200-day simple moving average of $26.25. Pfizer Inc. has a 1-year low of $23.58 and a 1-year high of $28.75. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The stock has a market cap of $159.59 billion, a price-to-earnings ratio of 36.84 and a beta of 0.34.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business’s revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts expect that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. Pfizer’s payout ratio is currently 226.32%.

Analysts Set New Price Targets

PFE has been the subject of a number of analyst reports. Wolfe Research restated an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. Guggenheim reduced their price objective on Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective on the stock in a research note on Tuesday, June 9th. JPMorgan Chase & Co. dropped their target price on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Wednesday, July 8th. Finally, Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus target price of $28.28.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.